- Poster presentation
- Open Access
P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
© Carter et al; licensee BioMed Central Ltd. 2014
- Published: 28 February 2014
- Allergic Rhinitis
- Allergic Rhinitis
- Symptom Relief
- Seasonal Allergic Rhinitis
- Perennial Allergic Rhinitis
Allergic rhinitis (AR) is poorly controlled. Treated patients, even those on multiple therapies still experience symptoms. In a UK survey, 70.5% of moderate-to-severe AR patients took ≥2 medications (either Rx or over the counter) in an attempt to achieve better and faster symptom relief.
To explore the extent of co-prescribing by UK general practitioners (GPs) during the hay-fever season in patients with seasonal AR (SAR), perennial AR (PAR), and comorbid asthma.
A retrospective database study using the Optimum Patient Care Research Database consisting of data extracted from GP records supplemented with patient-reported outcomes from questionnaires. Patients included in the analysis had a recorded AR diagnosis and ≥1 AR therapy scripts during 1st March 2010 to 31st Augu37st 2010.
1st March 2010 to 31st August 2010
Therapy, n (%)
Total on combinations
Season End, n (%)
Non Asthma (n=13594)
Start of season
End of season
In contrast to previous surveys, these data relate to prescriptions only and show a high level of co-prescribing behavior among UK GPs. There was a significant shift to combination therapy during the season, particularly for PAR patients, with strong co-prescription evident regardless of asthma co-morbidity. These data indicate that (i) UK GPs are aware that current therapy provides insufficient symptom relief, (ii) that AR is a costly disease to treat requiring several GP visits over the season for therapy modification and (iii) there is a need for an AR therapy which provides more complete symptom relief.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.